863 related articles for article (PubMed ID: 16061846)
1. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
2. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
3. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
4. [A combination phase I/II study--dose escalation plan].
Yamamoto N
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
[TBL] [Abstract][Full Text] [Related]
5. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
6. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
Su Z
Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
[TBL] [Abstract][Full Text] [Related]
7. Patient specific dosing in a cancer phase I clinical trial.
Babb JS; Rogatko A
Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
[TBL] [Abstract][Full Text] [Related]
8. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
9. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
11. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
12. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
Braun TM; Thall PF; Nguyen H; de Lima M
Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
[TBL] [Abstract][Full Text] [Related]
13. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
14. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
Tournoux C; De Rycke Y; Médioni J; Asselain B
Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
[TBL] [Abstract][Full Text] [Related]
15. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
16. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
Feinberg J; Japour AJ
Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
[TBL] [Abstract][Full Text] [Related]
17. An improved method of evaluating drug effect in a multiple dose clinical trial.
Shen L
Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
[TBL] [Abstract][Full Text] [Related]
18. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
19. Critical assessment of international clinical development programmes for new antihypertensive drugs.
Ménard J
J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
[TBL] [Abstract][Full Text] [Related]
20. [Phase I cancer trials methodology].
Le Tourneau C; Faivre S; Raymond E; Diéras V
Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
